An upcoming event that promises to be both impactful and influential in the realm of cancer research.
Join us in our Sydney International Conference, ‘Advancing Multi-Omics to the Clinic’, Sydney, Australia, 18th-19th November 2024. Through this two-day meeting, internationally renowned experts in proteomics, genomics, cancer management, biomarker and drug discovery will share their progress towards addressing the challenges and opportunities of multi-omic data integration in cancer management, with a special focus on the role of proteomics in advancing biomarker development and drug discovery.
Our event will serve as a platform for renowned experts to share their latest findings, advancements, and insights into the challenges and opportunities surrounding multi-omic data integration in cancer management. Of particular focus will be the pivotal role of proteomics in driving biomarker development and accelerating drug discovery processes.
Speakers
Prof Ruedi Aebersold | ETH, Zurich | Switzerland
Prof Bernhard Kuster | TUM, Munich | Germany
Dr Bing Zhang | BCM, Houston | USA
Dr Jennifer Van Eyk | Cedars-Sinai, Los Angeles | USA
Prof David Thomas | UNSW, Sydney | Australia
Prof Christopher Whelan | USC, Los Angeles | USA
Prof Anna DeFazio | USYD, Sydney | Australia
Prof Lois Holloway | Ingham Institute, Sydney | Australia
Vanessa Tyrrell | CCI, Sydney | Australia
Prof Zornitza Stark | Australian Genomics, Melbourne | Australia
Agenda
Session 1 - The Future of Omics in the Clinic: This session will explore the emerging trends and future directions of omics technologies in clinical settings, focusing on how genomics, proteomics, and other omics can revolutionise patient care and personalised medicine
Session 2 - AI & ML for Advancing Omics to the Clinic: This session will delve into the role of artificial intelligence and machine learning in enhancing the analysis and application of omics data, highlighting innovative algorithms and models that are driving precision medicine
Session 3 - Drug Target Identification: This session will cover methodologies and technologies used to identify novel drug targets through collecting and analysing omics data, emphasising the potential for new therapeutic developments and personalised treatment plans
Session 4 - Translating Cancer Signatures to the Clinic: This session will discuss the practical approaches and experiences in translating molecular cancer signatures into clinical practice, aiming to improve diagnostics, prognostics, and treatment strategies for cancer patients
Session 5 - Multi-Omic Data Integration: This session will focus on the integration of various omics data types, such as genomics, transcriptomics, proteomics, and metabolomics, to create comprehensive biological insights and advance clinical research and applications
Session 6 - Regulatory Challenges and Commercialisation: This session will address experiences in the regulatory challenges and commercialisation strategies for bringing omics technologies and findings from research to the clinic, including discussions on compliance, intellectual property, and market access.
Contact
Prof Roger Reddel: [email protected]
Prof Phil Robinson: [email protected]
Dr Qing Zhong: [email protected]